This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $45.07, moving +1.81% from the previous trading session.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.
Novavax (NVAX) Starts COVID-19 Booster Study in Adolescents
by Zacks Equity Research
Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.
Time for Reopening-Friendly Travel & Leisure ETFs?
by Sanghamitra Saha
As the pandemic is slowly turning into an endemic, leisure and travel stocks have flied higher.
Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study
by Zacks Equity Research
Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $54.59, marking a -1.03% move from the previous day.
Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland
by Zacks Equity Research
Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $60.63, moving +1.9% from the previous trading session.
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Seeks EU Nod for COVID-19 Vaccine in Kids
by Zacks Equity Research
Novavax (NVAX) seeks label expansion for its COVID-19 vaccine in adolescents aged 12-17 years in the European Union. Currently, the vaccine is authorized for use in adults.
Novavax (NVAX) Stock Moves -1.47%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $73.65, marking a -1.47% move from the previous day.
Why Is Novavax (NVAX) Down 5.9% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $81.45, marking a +1.58% move from the previous day.
Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.
Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.
Pfizer (PFE) Gets Breakthrough Therapy Status for RSV Vaccine
by Zacks Equity Research
Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.
Novavax's (NVAX) Q4 Loss Wider Than Expected, 2022 View Weak
by Zacks Equity Research
Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.
Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -681.82% and 42.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Time To Buy The Fear Dip?
by Daniel Laboe
Innovation's capitulation may be sold out as high-growth bears run out of selling fuel, leaving the door wide open for stock pickers to get into their favorite next-gen stocks
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $86.55, moving -0.67% from the previous trading session.
Pfizer (PFE) Plans to Delay Comirnaty for Kids EUA Submission
by Zacks Equity Research
Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.
Novavax's (NVAX) COVID Vaccine Achieves Study Goal in Kids
by Zacks Equity Research
Novavax's (NVAX) COVID vaccine achieves 80% overall efficacy in a phase III study in adolescents aged between 12 and 17.